Vanda Pharmaceuticals Inc.

Overview

Compare with Amarin Corporation, Ideaya Biosciences (United States) or Puma Biotechnology, or pick any stock.

• TickerVNDA on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersWashington, United States²
• Incorporated inDE³
• Business address2200 Pennsylvania Ave Nw, Suite 300E, Washington, Dc 20037³
• Filer categoryAccelerated filer³
• Legal formCorporation²
• LEI529900AY8VOOQBKJ0O70²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 3590747²

See how the biggest companies compare on our leaderboards

All forward-looking statements in this report are expressly qualified in their entirety by the cautionary statements contained throughout this report. We caution you not to rely too heavily on such forward-looking statements. Each forward-looking statement speaks only as of the date of this Annual Report, and we undertake no obligation, and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.⁴ From its latest annual report

Corporate structure

Vanda Pharmaceuticals Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Vanda Pharmaceuticals Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our headquarters office consists of a total of 43,462 square feet of office space located at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. under operating leases and subleases that expire between 2026 and 2028 and certain of these leases are subject to renewal options. In addition, we have 2,880 square feet of office space in London, England under an operating lease that has a lease term ending in 2026, and other short-term leases. We believe that these facilities are suitable and adequate

to meet our anticipated near-term needs. We anticipate that following the expiration of the leases, additional or alternative space will be available at commercially reasonable terms.

Item 2 of the 10-K filed Feb 12, 2026.⁴

Leadership

Who has led Vanda Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMihael Hristos Polymeropoulos Apr 12, 2006 to now¹³
• ChairArgeris N. Karabelas Apr 12, 2006 to Dec 14, 2006¹⁴
• PresidentMihael Hristos Polymeropoulos Jan 5, 2010 to now¹⁵
• Chief financial officerKevin Patrick Moran Mar 24, 2020 to now¹⁶
• Chief financial officerStephanie Rast Irish Jan 20, 2009 to Feb 23, 2010¹⁷
• Chief financial officerSteven A. Shallcross Apr 12, 2006 to Jan 8, 2008¹⁸

Timeline

1. Aug 5, 20268-K Results of operations⁴⁷
2. Jun 5, 20268-K Shareholder vote⁴⁸
3. May 6, 20268-K Results of operations⁴⁹
4. Apr 22, 20268-K Executive or director change⁵⁰
5. Apr 2, 20268-K Executive or director change⁵¹
6. Mar 10, 20268-K Regulation FD disclosure⁵²
7. Feb 23, 20268-K Other events⁵³
8. Feb 19, 20268-K Executive or director change⁵⁴
9. Feb 11, 20268-K Results of operations⁵⁵
10. Jan 8, 20268-K Other events⁵⁶
11. Dec 31, 20258-K Other events⁵⁷
12. Dec 4, 20258-K Other events⁵⁸
13. Apr 12, 2006New chief executive Mihael Hristos Polymeropoulos becomes CEO¹³

Calendar

Coming up

1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.38) a share, on Oct 29, 2025.⁵⁹

When it reported results

1. Aug 5, 2026Reported quarterly or annual results⁴⁷
2. May 6, 2026Reported quarterly or annual results⁴⁹
3. Feb 11, 2026Reported quarterly or annual results⁵⁵
4. Oct 29, 2025Reported quarterly or annual results⁶⁰
5. Jul 31, 2025Reported quarterly or annual results⁶¹
6. May 7, 2025Reported quarterly or annual results⁶²
7. Feb 13, 2025Reported quarterly or annual results⁶³
8. Nov 6, 2024Reported quarterly or annual results⁶⁴

Drug trials and FDA: coming up

1. Oct 2026Phase 2 trial readout expected Phase 2 trial of iloperidone in Hypertension: primary completion expected Oct 2026 (ClinicalTrials.gov NCT07090161).⁶⁵
2. Dec 1, 2026Phase 3 trial readout expected Phase 3 trial of Tradipitant in Nausea and Vomiting: primary completion expected Dec 1, 2026 (ClinicalTrials.gov NCT07446439).⁶⁶
3. Dec 2026Phase 3 trial readout expected Phase 3 trial of VQW-765 in Social Anxiety Disorder (SAD): primary completion expected Dec 2026 (ClinicalTrials.gov NCT07221578).⁶⁷
4. Mar 2027Phase 1/2 trial readout expected Phase 1/2 trial of VCA-894A in Charcot Marie Tooth Disease (CMT): primary completion expected Mar 2027 (ClinicalTrials.gov NCT07223632).⁶⁸
5. Sep 30, 2027Phase 3 trial readout expected Phase 3 trial of Tradipitant in Motion Sickness: primary completion expected Sep 30, 2027 (ClinicalTrials.gov NCT06138613).⁶⁹

Drug trials and FDA: recently

1. Sep 4, 2026Phase 3 trial completed Phase 3 trial of Tasimelteon in Sleep Wake Disorders: primary completion Sep 4, 2026, no results posted yet (ClinicalTrials.gov NCT04652882).⁷⁰
2. Mar 30, 2026Phase 3 trial completed Phase 3 trial of Tradipitant in Idiopathic Gastroparesis: primary completion Mar 30, 2026, no results posted yet (ClinicalTrials.gov NCT06836557).⁷¹
3. Feb 20, 2026FDA approval FDA approved Bysanti (milsaperidone), a new molecular entity (NDA 220358).⁷²
4. Dec 30, 2025FDA approval FDA approved Nereus (tradipitant), a new molecular entity (NDA 220152).⁷³
5. Feb 21, 2025Phase 3 trial completed Phase 3 trial of Tradipitant and Open Label Tradipitant in Idiopathic Gastroparesis: primary completion Feb 21, 2025, results posted Sep 24, 2026 (ClinicalTrials.gov NCT04028492).⁷⁴
6. Apr 2, 2024FDA approved a new use FDA approved an efficacy supplement for Fanapt (iloperidone), a new use or patient group (NDA 022192, supplement 23).⁷⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

284 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 69 major events, 109 insider forms, 33 large holders, 53 other. The latest 20:

1. Oct 9, 2026SCHEDULE 13G/A EDGAR
2. Aug 19, 2026SCHEDULE 13G EDGAR
3. Aug 13, 2026SCHEDULE 13G EDGAR
4. Aug 6, 202610-Q EDGAR
5. Aug 5, 20268-K EDGAR
6. Jun 8, 20264 EDGAR
7. Jun 8, 20264 EDGAR
8. Jun 8, 20264 EDGAR
9. Jun 8, 20264 EDGAR
10. Jun 8, 20264 EDGAR
11. Jun 8, 20264 EDGAR
12. Jun 8, 20264 EDGAR
13. Jun 8, 20263 EDGAR
14. Jun 5, 2026S-8 EDGAR
15. Jun 5, 20268-K EDGAR
16. May 20, 20264 EDGAR
17. May 12, 2026SCHEDULE 13G EDGAR
18. May 7, 202610-Q EDGAR
19. May 6, 20268-K EDGAR
20. May 5, 2026EFFECT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

65 open-market trades by officers, directors and large owners since October 2021: 11 buys and 54 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 4 filings Jul 1, 2025 to Oct 9, 2026⁷⁶
• AQR CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Aug 13, 2026⁷⁷
• State Street CorporationSCHEDULE 13G, 4 filings Feb 14, 2022 to May 12, 2026⁷⁸
• BlackRock Portfolio Management LLCSCHEDULE 13G/A, 3 filings Apr 15, 2025 to Apr 29, 2026⁷⁹
• VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 2026⁸⁰
• BlackRockSCHEDULE 13G/A, 7 filings Jan 26, 2022 to Feb 7, 2025⁸¹
• RENAISSANCE TECHNOLOGIES LLCSC 13G/A, 3 filings Feb 11, 2022 to Feb 13, 2024⁸²
• DIMENSIONAL FUND ADVISORS LPSC 13G/A, 2 filings Feb 10, 2023 to Feb 9, 2024⁸³
• Macquarie GroupSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁸⁴
• Palo Alto Investors LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁸⁵
• ARMISTICE CAPITAL, LLCSC 13G/A, 1 filing Feb 15, 2022⁸⁶

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Vanda Pharmaceuticals Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARVanda Pharmaceuticals Inc.¹
• CIK0001347178
• Employer ID (EIN)03-0491827⁴
• Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address2200 Pennsylvania Ave Nw, Suite 300E, Washington, DC 20037¹
• Phone202-734-3400¹
• Shares outstanding60,462,687 as of Jul 30, 2026¹¹
• Public float$268.7M as of Jun 30, 2025⁴
• AuditorPricewaterhouseCoopers LLP, Washington, District of Columbia PCAOB ID 238; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceDec 29, 2005¹
• Filings1,332 in all: 4 (507), 8-K (302), SC 13G/A (140), 10-Q (62), 3 (57), SC 13G (53), DEFA14A (24), S-8 (22)¹
  All 38 form types

  10-K (20), DEF 14A (20), 144 (19), 4/A (9), UPLOAD (9), CORRESP (8), S-1/A (8), 424B5 (7), CT ORDER (7), SCHEDULE 13G/A (7), EFFECT (6), 5 (5), S-3 (5), SCHEDULE 13G (5), 8-K/A (4), ARS (4), 8-A12B/A (3), SC 13D/A (3), 10-K/A (2), 424B4 (2), 8-A12B (2), S-1 (2), 8-A12G (1), ARS/A (1), DFAN14A (1), PREC14A (1), S-1MEF (1), S-3/A (1), S-3MEF (1), SC 13D (1)

• Latest filingsAnnual report (10-K) Feb 12, 2026
  Quarterly report (10-Q) Aug 6, 2026
  Proxy statement (DEF 14A) Apr 23, 2026
  Latest 8-K (8-K) Aug 5, 2026

Securities registered for trading

From the cover page of the 10-K filed Feb 12, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Vanda Pharmaceuticals Inc. names in Item 1A of its 10-K filed Feb 12, 2026: 63 risks under these headings, as written.⁴

• Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock.
• Because of the following risk factors, as well as other risk factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.
• Risks Related to our Business and Industry
• We are dependent on the commercial success of our commercial products. In the U.S., HETLIOZ® competes with generic versions of HETLIOZ® and we could experience increased generic competition in the near term.
• As a result of the decision in favor of generic drug companies in connection with our HETLIOZ® patent litigation, we have faced generic competition and our revenues and results of operations could be further affected by the launch of additional generic versions of HETLIOZ® in the U.S.
• Future performance of our commercial products may be impacted by a number of factors including competing products or unanticipated safety issues. If our commercial products are not successful in gaining broad commercial acceptance, our business would be harmed.
• We are subject to uncertainty relating to pricing and reimbursement policies in the U.S., including recent and future health reform measures, which, if not favorable for our products, could hinder or prevent our products’ commercial success.
• We have encountered third-party payors that refuse to cover or reimburse prescriptions written for HETLIOZ® and patients who are unable to navigate the coverage or reimbursement processes established by these third-party payors. If this trend continues, the commercial success of HETLIOZ® may be limited, and our business and results of operations may be materially harmed.
• If the FDA does not approve our NDA filing for the use of NEREUSTM for patients with gastroparesis, our business may be harmed, and the market price of our stock could decline.
• If the FDA does not approve our sNDAs for HETLIOZ® for the treatment of jet lag disorder or insomnia, continued development of HETLIOZ® for the treatment of jet lag disorder and insomnia may be significantly delayed or terminated, our business will be significantly harmed and the market price of our stock could decline.
• We might not obtain the necessary regulatory approvals to commercialize current product candidates, including BysantiTM and imsidolimab.
• Disruptions at the FDA and other government agencies caused by, among other things, government shutdowns, could hinder their ability to hire, retain or deploy key leadership and other personnel, conduct inspections of manufacturing facilities or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.

Legal proceedings

Information with respect to this item may be found in Note 18, Legal Matters, to the consolidated financial statements in Part II, Item 8 of this annual report on Form 10-K, which is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.⁴